Updated: January 18, 2026

Yusimry Shortage Update: What Patients Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Current Yusimry Shortage Status (2026)
Why Patients Still Can't Find Yusimry
1. PBM Formulary Decisions Limit Retail Stocking
2. Insurance Coverage Is Inconsistent
3. Specialty Pharmacy Distribution Requirements
Yusimry Timeline: From Approval to Today
Will Yusimry Become Easier to Find?
What You Can Do Right Now

Is there a Yusimry shortage in 2026? The FDA hasn't listed one, but patients are still struggling to fill prescriptions. Here's the full picture and what you can do.

If you're struggling to fill your Yusimry prescription, you might be wondering: is there a Yusimry shortage? The short answer is no — Yusimry is not currently listed on the FDA drug shortage database. But that doesn't mean it's easy to find. Here's the full picture of Yusimry availability in 2026, why patients are still having difficulty, and what your options are.

Current Yusimry Shortage Status (2026)

As of 2026, Yusimry (adalimumab-aqvh) is NOT listed on:

The FDA's drug shortage database (accessdata.fda.gov/scripts/drugshortages)

The ASHP (American Society of Health-System Pharmacists) drug shortage list

Coherus BioSciences (and its distribution partner Meitheal Pharmaceuticals) continues to manufacture and distribute Yusimry. The supply chain is intact. The issue is not a shortage — it's a market access problem.

Why Patients Still Can't Find Yusimry

Despite not being in an official shortage, many patients report difficulty filling Yusimry prescriptions. Here are the main reasons:

1. PBM Formulary Decisions Limit Retail Stocking

The three largest pharmacy benefit managers (CVS Caremark, Express Scripts, OptumRx) collectively control about 80% of US prescriptions. In 2024, each launched private-label versions of other adalimumab biosimilars — specifically Hyrimoz, Cyltezo/Simlandi, and Amjevita. Yusimry has no such arrangement, which means pharmacies in these networks have little incentive to stock it. By mid-2024, Yusimry held only about 3% of the adalimumab biosimilar market.

2. Insurance Coverage Is Inconsistent

Most insurance plans prefer specific adalimumab biosimilars based on PBM contract negotiations. If Yusimry isn't on your plan's preferred tier, you may face prior authorization requirements, step therapy mandates (requiring you to try another biosimilar first), or higher cost-sharing. This is particularly challenging for patients who were prescribed Yusimry specifically.

3. Specialty Pharmacy Distribution Requirements

Like all adalimumab biosimilars, Yusimry is a specialty medication. Most insurance plans require patients to use a designated specialty pharmacy — not a local retail pharmacy. If a patient doesn't know this, they may go to CVS or Walgreens and be told the medication isn't available, when in reality they need to use a specialty channel.

Yusimry Timeline: From Approval to Today

December 17, 2021: FDA approves Yusimry (adalimumab-aqvh) as the seventh adalimumab biosimilar.

July 2023: Yusimry launches in the US at a list price of $995 per carton — the lowest announced price for any adalimumab biosimilar at launch, representing ~85% off Humira's price.

July 2023: SmithRx and RxPreferred partner with Cost Plus Drugs to offer Yusimry at $569.27 (plus fees) — the most affordable route for uninsured and underinsured patients.

2024-2026: Major PBMs launch private-label adalimumab programs. Yusimry is not included in any private-label arrangement, resulting in limited retail pharmacy stocking.

Will Yusimry Become Easier to Find?

The adalimumab biosimilar market continues to evolve. As the market matures, formulary decisions will change and new PBM contracts may shift. Yusimry's strong price point ($639 average per prescription in 2024 employer data) is a significant advantage if payers prioritize cost. However, absent a major PBM private-label deal, retail availability is likely to remain limited in the near term.

What You Can Do Right Now

Search with medfinder: medfinder.com calls pharmacies near you to check Yusimry availability and texts you the results.

Try Cost Plus Drugs: Yusimry is available at costplusdrugs.com for $569.27 plus dispensing and shipping fees.

Use the Yusimry Solutions Copay Card: Eligible commercially insured patients can pay as little as $0. Call 1-800-987-4679.

Talk to your doctor: If Yusimry is impossible to get through your insurance, your doctor can prescribe another adalimumab biosimilar that is on your formulary — the switch is clinically safe.

For a step-by-step walkthrough on locating Yusimry, see our guide: How to Find Yusimry in Stock Near You.

Frequently Asked Questions

No. As of 2026, Yusimry (adalimumab-aqvh) is not listed on the FDA drug shortage database or the ASHP shortage list. Coherus BioSciences continues to manufacture and distribute Yusimry. Availability challenges are due to PBM formulary dynamics and limited retail pharmacy stocking.

No. Yusimry has not been listed on the FDA drug shortage database since its December 2021 approval and July 2023 launch. Its availability challenge is a market access issue, not a manufacturing or supply chain shortage.

Yusimry does not have a private-label arrangement with any of the three major PBMs (CVS Caremark, Express Scripts, OptumRx). These PBMs collectively control about 80% of US prescriptions, and pharmacies stock based on their contracts. Without a PBM deal, Yusimry has very limited retail pharmacy shelf space.

Possibly. The adalimumab biosimilar market continues to evolve. Yusimry's very low price point ($639 average per prescription in employer data) is a strong argument for cost-focused payers. However, without a major PBM deal, significant improvements in retail availability are uncertain in the near term.

Act immediately. Contact your specialty pharmacy to expedite your refill, call your insurance for prior authorization status, and ask your doctor about bridge options. You can also check Cost Plus Drugs (costplusdrugs.com) for cash-pay access at $569.27 plus fees. Do not skip doses without medical guidance.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards